As Atf3−/− mice, unlike Atf4−/− mice, are developmentally normal [52], drugging ATF3 would be a better strategy than targeting ATF4 for harnessing ferroptosis to treat human diseases including cancer. This evidence concerns the gene ATF4 and cancer.